Form 4: Zenas BioPharma CEO Reports Conversion of Preferred Stock and Option Grant Following IPO

CEO Leon O. Moulder Jr. reports the automatic conversion of preferred stock to common stock and the grant of stock options following Zenas BioPharma's initial public offering.

Summary

• Leon O. Moulder Jr., CEO of Zenas BioPharma, filed a Form 4 detailing changes in beneficial ownership.
• The filing reports the automatic conversion of Series Seed, Series A, and Series B convertible preferred stock into common stock on September 16, 2024, upon the closing of the company's IPO.
• The conversion ratio was 8.6831-for-1 for all preferred stock series.
• Moulder also acquired 1,486,000 stock options on September 12, 2024, vesting over 4 years.
• Moulder's holdings include both direct and indirect ownership through Tellus BioVentures LLC.
• Moulder disclaims beneficial ownership of securities held by Tellus BioVentures LLC except to the extent of his pecuniary interest therein.

Sentiment

Score: 7

Explanation: The document reflects standard procedures following an IPO, with no immediately concerning information. The conversion of preferred stock and option grants are generally viewed as positive signs of alignment between management and shareholders.

Positives

• The conversion of preferred stock to common stock simplifies the company's capital structure following the IPO.
• The grant of stock options aligns management's interests with those of shareholders.

Management Comments

• Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their ownership positions, particularly after significant events like an IPO. This filing indicates the CEO's holdings and the impact of the IPO on those holdings.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biopharmaceutical industry, often vesting over a multi-year period to incentivize long-term performance.
• The vesting schedule of the options is fairly standard, with 25% vesting after one year and the remainder vesting monthly over the following three years, similar to practices at companies like Amgen and Gilead Sciences.
• Automatic conversion of preferred stock upon an IPO is a typical feature designed to simplify the capital structure and align the interests of all shareholders, as seen in other biotech IPOs such as that of BioNTech.

Stakeholder Impact

• Shareholders will see a simplified capital structure with the conversion of preferred stock to common stock.
• Employees may be motivated by the CEO's increased alignment with shareholder interests through stock options.

Key Dates